Arthroscopy Devices Market Outlook:
Arthroscopy Devices Market size was USD 7.5 billion in 2024 and is estimated to reach USD 16.9 billion by the end of 2037, expanding at a CAGR of 6.7% during the forecast period, i.e., 2025-2037. In 2025, the industry size of arthroscopy devices is evaluated at USD 7.9 billion.
The worldwide patient pool effectively requires arthroscopy device procedures, which in turn are expanding, owing to a surge in musculoskeletal diseases, especially sports injuries and osteoarthritis. According to an article published by the Centers for Disease Control and Prevention (CDC), more than 59.5 million adults in the U.S. are readily affected by arthritis, with shoulder and knee conditions accounting for a substantial portion of surgical interventions. In addition, the World Health Organization (WHO) has estimated that osteoarthritis will be the fourth-largest cause of disability by the end of 2030 globally, further enhancing the demand for the market.
Furthermore, the producer price index has witnessed an increase of 3.5% for medical and surgical instruments yearly, which is positively influenced by a rise in supply chain risks, along with material expenses. Besides, the consumer price index has increased by 4.2% for orthopedic procedures year-over-year (YoY) basis, highly attributed to labor expenditure and progressive technology implementation. Meanwhile, the aspect of research, development, and deployment-based investments is considered to remain robust, with the National Institutes of Health (NIH) providing USD 485 million as of 2024, particularly for minimally invasive advancements, such as the artificial intelligence (AI)-powered arthroscopy, thus suitable for the global market growth.
Arthroscopy Devices Market - Growth Drivers and Challenges
Growth Drivers
-
Transition towards ambulatory and outpatient surgery facilities: There has been a sudden shift from hospitals to ASCs, which is optimistically transforming the overall market. ASCs constitute the capability to diminish expenses by an estimated USD 4,500 per case and, in turn, enhance patient convenience and drive 8.5% yearly growth, especially for facility deployments. Besides, manufacturers are catering to portable arthroscopy systems with precision, which are readily tailored for AI tools and ASCs to modernize surgical workflows, thus creating a positive impact on the market.
-
AI adoption and technological innovations: Both robots and AI are revolutionizing the global market, with Stryker’s Mako system enhancing accuracy by approximately 55%. In addition, Smith & Nephew’s AI imaging effectively reduces surgery duration by 30%, and is currently utilized in more than 180 EU hospitals. Besides, manufacturers are projected to invest in conducting surgeon education programs, along with partnerships with technology organizations to escalate the integration of arthroscopy devices, and ensure collaboration with administrative reforms, including the U.S. FDA, to fast-track the approval process.
Manufacturer Strategies Shaping the Arthroscopy Devices Market
Leading manufacturers in the international arthroscopy devices market are focused on leveraging ASC-driven partnerships, strategic acquisitions, and product innovation, with the objective to strengthen their respective market positions. For instance, as per the FDA government report, Stryker’s Mako robotic system has successfully captured an additional market share of 17% in 2023, highly fueled by enhancing precision through AI implementation. Likewise, Smith & Nephew made an expansion of its 4K imaging portfolio and secured USD 222 million in the newest ASC contracts. Meanwhile, the acquisition of a robotics startup firm by Arthrex has bolstered its revenue in the EU by almost 12.5%, thereby suitable for market expansion.
Revenue Potential for Arthroscopy Device Manufacturers (2023-2025)
|
Company |
Strategy |
Revenue Impact (2023) |
Projected Growth (2025) |
|
Stryker |
Mako robotics expansion |
+USD 488 million (17% market share) |
USD 1.3 billion (Robotics segment) |
|
Smith & Nephew |
4K imaging & ASC partnerships |
+USD 222 million (New contracts) |
9.2% CAGR (Imaging) |
|
Arthrex |
Robotics startup acquisition |
+12.5% EU revenue |
USD 855 million (Global sales) |
|
Johnson & Johnson |
Velys cost-reduction platform |
18.5% lower procedure costs |
USD 1.6 billion (Platform adoption) |
Emerging Feasibility Models Driving Arthroscopy Market Expansion
The international arthroscopy devices market is being readily reshaped by the adoption of robotic surgery, bundled pricing strategies, and localized partnerships. For instance, it has been witnessed that state hospitals and suppliers in India have partnered with each other to provide subsidized procedures, which in turn, increased revenue by almost 15% between 2022 and 2024. Likewise, the existence of ASC-based reimbursement policies in Germany has bolstered outpatient arthroscopy adoption by an estimated 19%. Meanwhile, the U.S. observed a surge in its revenue by 9.5% in 2023, owing to Medicare’s expanded ASC coverage, all of which caters to the market upliftment.
Feasibility Models for Market Expansion (2022-2024)
|
Region |
Model |
Revenue Impact |
Key Driver |
|
India |
Hospital partnerships |
+15% revenue |
Subsidized procedures |
|
Germany |
ASC reimbursement policies |
+19% adoption rate |
Outpatient cost savings |
|
U.S. |
Medicare ASC expansion |
+9.5% market revenue |
Policy-driven coverage |
Challenges
-
Delays in MDR compliance and regulations: The presence of evolving and strict administrative requirements effectively creates significant market entry barriers, which negatively impact the arthroscopy devices market. For instance, the Medical Device Regulation (MDR) in the EU has enhanced its compliance cost by almost 45%, with small-scale organizations struggling to provide funds that are effectively needed for documentation as well as post-market surveillance. Besides, the majority of Class IIb devices currently require Notified Body reviews, which usually takes 20 to 26 months in comparison to 7 to 10 months under previous regulations.
-
Expensive out-of-pocket costs: The aspect of affordability is considered a severe barrier for the global arthroscopy devices market, in both emerging and developing economies. For instance, in Germany, there has been an increase in patient co-payments by more than €1,150 in 2024, which has made arthroscopy inaccessible for an estimated 27% of patients, especially the elderly population with fixed income. Meanwhile, approximately 95% of healthcare in India is paid through out-of-pocket, and a single USD 3,250 procedure is equivalent to 19 months’ wages for average workers, thus causing a hindrance in the market growth.
Arthroscopy Devices Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.7% |
|
Base Year Market Size (2024) |
USD 7.5 billion |
|
Forecast Year Market Size (2037) |
USD 16.9 billion |
|
Regional Scope |
|
Arthroscopy Devices Market Segmentation:
End User Segment Analysis
The hospitals segment is anticipated to garner the largest share of 55.8% in the arthroscopy devices market by the end of 2037. The segment’s growth is highly fueled by reimbursement benefits, innovative infrastructure, and complicated surgical caseloads. According to the CMS government report, the healthcare industry in the U.S. accounts for approximately 66% of knee arthroscopy procedures, which is further supported by Medicare’s inpatient coverage reforms. Likewise, the hospital-centric system in Germany successfully performs 75% of arthroscopies, owing to the presence of strict ASC regulations, thereby creating a positive impact on the market.
Application Segment Analysis
The knee arthroscopy segment is projected to hold the second-largest share of 47.8% in the arthroscopy devices market by the end of the forecast duration. The segment’s upliftment is highly driven by a surge in sports injury rates, along with the occurrence of osteoarthritis. According to the CMS government report, the U.S. has recorded more than 1.1 million knee scopes every year, effectively propelled by Medicare’s 77% coverage of procedures, particularly for patients more than 65 years of age. Likewise, there has been an increase in Germany’s knee arthroscopy volumes by 13% since 2022, which is connected to robotic surgery-based reimbursement policies.
Our in-depth analysis of the arthroscopy devices market includes the following segments:
|
Segment |
Subsegment |
|
End User |
|
|
Application |
|
|
Product Type |
|
|
Technology |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Arthroscopy Devices Market - Regional Analysis
North America Market Insights
North America in the arthroscopy devices market is considered the dominating region with the highest share of 47.8% by the end of 2037. The market’s growth in the region is effectively propelled by the presence of strong reimbursement policies, innovative ASC infrastructure, and high procedural volumes. Canada is contributing almost 10.5% of market revenue, which is driven by the presence of provincial health and medical investments. Besides, key trends, including a rise in outpatient migration, accounting for 67% of ASCA surgeries, AI-driven imaging systems, and accelerated robot-based implementation, accounting for 35% of procedures, all are positively influencing the market in the region.
The arthroscopy devices market in the U.S. is significantly growing with an expected global market share of 40.2%, which accounts for USD 8.2 billion in yearly revenue by the end of 2037. According to the CMS government report, Medicare has readily spent USD 2.2 billion annually on arthroscopy, which provides a 75.8% coverage of knee procedures, specifically for senior citizens. In addition, the AHRQ government has reported that ASCs can perform 74.5% of meniscal repairs, which can diminish expenses by more than USD 4,500 per case. Meanwhile, the FDA government report has stated that disposable scopes tend to grow rapidly at 9.4%, which has combated infections by 42%.
The arthroscopy devices market in Canada is projected to reach USD 925 million by the end of 2037, along with a 6.2% growth rate. Ontario is currently leading with 48.5% of procedures, along with an investment of USD 455 million for robotic systems. Besides, the waiting duration in the country has lowered by almost 27%, owing to the provision of federal funding by ASCs. Furthermore, single-use scopes are gaining increased traction, with a 28.5% adoption rate, while knee arthroscopy is deliberately dominating with a 55% share, thus suitable for market upliftment in the country.
APAC Market Insights
Asia Pacific in the arthroscopy devices market is considered the fastest-growing region with an expected growth rate of 8.5% between 2025 and 2037, effectively attributed to health and medical modernization, sports injuries, and a surge in the geriatric population. China’s market is projected to expand with a 9.1% growth rate, highly backed by the NMPA’s fast-track acceptances for regional AI scopes. Meanwhile, there has been an increase in the demand for arthroscopy devices in India, surging to 2.5 million yearly procedures, of which 85% caters to out-of-pocket expenses that tend to limit accessibility. Besides, the aspects of robot-based adoption, along with ASC investments, are positively impacting the market in the region.
The arthroscopy devices market in China is gaining increased traction since it has been projected that the country will capture almost 33% of the region’s revenue by the end of the forecast timeline, along with a 9.3% growth rate. The market’s growth in the country is highly attributed to regional manufacturing and AI-powered scopes. As per an article published by the NMPA, the government has provided USD 2.7 billion to arthroscopy in 2023, which denotes a 27.5% yearly growth in robot-driven systems. Besides, more than 1.8 million knee procedures have been performed annually, owing to a surge in osteoarthritis cases, thus enhancing the market demand.
The arthroscopy devices market in India is projected to garner an estimated 25% of the overall region’s revenue by the end of the forecast duration, supported by a growth rate of 11.5%. As per a report published by the MoHFW, the government has augmented spending to an estimated USD 2.1 billion yearly, which covers more than 4.5 million procedures under the Ayushman Bharat initiative. Besides, knee scopes readily dominate the country’s share, accounting for almost 62%, based on which approximately 2.5 million patients are treated every year, thereby creating a positive impact on the market.
Europe Market Insights
Europe in the arthroscopy devices market is anticipated to grow at a rate of 5.7% during the forecast period, propelled by robotic surgery implementation, sports injuries, and a surge in the aging demographics. Germany is effectively dominating the region with a 37.5% share, further attributed to the €4.5 billion yearly spending and complete reimbursement policies for robot-based procedures. The UK readily follows with 25.8% of the share, of which 8.2% has been allocated as part of the NHS budget, accounting for £ 1.4 billion for arthroscopy. Besides, the EU Health Data Space initiative has invested €2.6 billion in AI-driven arthroscopy, thereby creating an optimistic outlook for the market.
The arthroscopy devices market in Germany is dominating the overall region with a share of 37.5%, owing to a complete reimbursement facility for robotic arthroscopy, which readily accounts for 52% of knee procedures. Besides, the provision of the €4.5 billion in yearly spending has positively reflected a 17% growth since 2021, with AI-powered navigation systems and devices effectively penetrating almost 47% of hospitals. Therefore, all these factors are positively responsible for uplifting the market in the country.
The arthroscopy devices market in the UK is also growing by capturing a share of 28% of the overall regional revenue. This has been possible with the provision of the NHS’s £1.4 billion arthroscopy budget that has prioritized ASC-driven care, catering to an estimated 66% of overall procedures, with the ultimate aim to combat costs by almost 31.5%. Besides, disposable scopes are gaining increasing traction, with a 25.5% adoption rate. Meanwhile, in 2023, the EU Health Fund’s €550 million injection has escalated the AI integration, with hospitals in London successfully achieving 36% rapid surgeries.
European Government Initiatives in Arthroscopy Devices (2021–2025)
|
Country |
Policy/Initiative |
Funding Allocated |
Launch Year |
Key Impact |
|
France |
"Innovative Medical Devices Program" |
€950 million (2023–2027) |
2023 |
Focus on disposable scopes & ASC adoption |
|
Italy |
"National Recovery Plan (PNRR) – Health" |
€225 million (2022–2026) |
2022 |
Robotic surgery subsidies (23% coverage) |
|
Spain |
"Digital Health Strategy" |
€333 million (2022–2025) |
2022 |
AI-integrated arthroscopy in 30 hospitals |
Key Arthroscopy Devices Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The worldwide arthroscopy devices market is effectively dominated by Europe and the U.S. firms, with Stryker accounting for 22.5% share, along with Johnson & Johnson accounting for 19% share, with both leading through AI and robotics integration. Besides, Smith & Nephew accounts for 17% of the global market share, with increased focus on single-use scopes, while Arthrex caters to a 13% share, and readily dominates sports medicine. Meanwhile, regulatory agility and cost optimization are other strategies that are implemented by organizations to uplift the market. For instance, GPC have effectively targeted emerging economies with budget-friendly disposable, thereby suitable for market development.
Here is a list of key players operating in the global market:
|
Company Name |
Country |
Market Share (2023) |
Industry Focus |
|
Stryker Corporation |
U.S. |
22.5% |
Robotics (Mako System), 4K visualization, disposable scopes |
|
Johnson & Johnson (DePuy Synthes) |
U.S. |
19% |
Advanced implants, fluid management systems |
|
Smith & Nephew |
UK |
17% |
AI-powered scopes, single-use instruments |
|
Arthrex |
U.S. |
13% |
Sports medicine, suture anchors, bioabsorbable implants |
|
Zimmer Biomet |
U.S. |
10% |
Knee & hip arthroscopy, robotic-assisted systems |
|
ConMed |
U.S. |
xx% |
RF ablation, fluid management, and electrosurgical devices |
|
Medtronic |
Ireland |
xx% |
Minimally invasive spine arthroscopy and navigation systems |
|
Karl Storz |
Germany |
xx% |
Endoscopic imaging, 3D visualization systems |
|
B. Braun |
Germany |
xx% |
Disposable arthroscopy instruments, fluid management |
|
Richard Wolf |
Germany |
xx% |
HD arthroscopes, modular surgical systems |
|
Medartis |
Switzerland |
xx% |
Precision instruments, biodegradable fixation solutions |
|
Trice Medical |
U.S. |
xx% |
Point-of-care arthroscopy (mi-eye 2 camera) |
|
Paragon 28 |
U.S. |
xx% |
Foot & ankle arthroscopy, specialized surgical tools |
|
GPC Medical |
India |
xx% |
Low-cost disposable instruments for emerging markets |
|
Biometrix |
Australia |
xx% |
Shoulder arthroscopy, biodegradable implants |
Below are the areas covered for each company in the arthroscopy devices market:
Recent Developments
- In March 2024, Johnson & Johnson declared that it received FDA acceptance for its Velys Robotic-Assisted Knee Scope, which tends to target almost 45% of cost reduction in comparison to conventional robotic systems.
- In January 2024, Stryker Corporation unveiled the InsightIQ+ AI-driven arthroscopy platform that integrates real-time surgical analytics with more than 3,500 visualizations, further diminishing procedure duration by 27%.
Author Credits: Radhika Pawar
- Report ID: 7818
- Published Date: Jun 26, 2025
- Report Format: PDF, PPT
